Tang Q, Zhao XS, Guo A, Cui RT, Song HL, Qi ZY, Pan Y, Yang Y, Zhang FF, Jin L. Therapeutic applications of adipose-derived stromal vascular fractions in osteoarthritis. World J Stem Cells 2022; 14(10): 744-755 [PMID: 36337155 DOI: 10.4252/wjsc.v14.i10.744]
Corresponding Author of This Article
Liang Jin, PhD, Professor, School of Life Science and Technology, China Pharmaceutical University, No. 24 Tongjiaxiang Avenue, Nanjing 211198, Jiangsu Province, China. ljstemcell@cpu.edu.cn
Research Domain of This Article
Cell Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Oct 26, 2022; 14(10): 744-755 Published online Oct 26, 2022. doi: 10.4252/wjsc.v14.i10.744
Therapeutic applications of adipose-derived stromal vascular fractions in osteoarthritis
Qi Tang, Xian-Sheng Zhao, Ao Guo, Ruo-Tong Cui, Huai-Le Song, Zi-Yang Qi, Yi Pan, Yue Yang, Fang-Fang Zhang, Liang Jin
Qi Tang, Ao Guo, Ruo-Tong Cui, Huai-Le Song, Zi-Yang Qi, Yi Pan, Yue Yang, Fang-Fang Zhang, Liang Jin, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Xian-Sheng Zhao, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China
Author contributions: Tang Q and Zhao XS contributed data collection and manuscript writing; Guo A, Cui RT, Song HL, Qi ZY, Pan Y, Yang Y contributed data analysis; Zhang FF, Jin L contributed study design and supervision; all authors have read and approve the final manuscript.
Supported byNational Natural Science Foundation of China, No. 82070801, No. 82100858, No. 82073227; China Postdoctoral Science Foundation, No. 2020M671661; Jiangsu Province Science Foundation for Youths, No. BK20200569; and Jiangsu Province Research Founding for Postdoctoral, No. 1412000016.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Liang Jin, PhD, Professor, School of Life Science and Technology, China Pharmaceutical University, No. 24 Tongjiaxiang Avenue, Nanjing 211198, Jiangsu Province, China. ljstemcell@cpu.edu.cn
Received: April 6, 2022 Peer-review started: April 6, 2022 First decision: June 22, 2022 Revised: July 8, 2022 Accepted: September 12, 2022 Article in press: September 12, 2022 Published online: October 26, 2022
Abstract
Osteoarthritis (OA) is considered to be a highly heterogeneous disease with progressive cartilage loss, subchondral bone remodeling, and low-grade inflammation. It is one of the world's leading causes of disability. Most conventional clinical treatments for OA are palliative drugs, which cannot fundamentally cure this disease. The stromal vascular fraction (SVF) from adipose tissues is a heterogeneous cell population. According to previous studies, it contains a large number of mesenchymal stem cells, which have been used to treat OA with good therapeutic results. This safe, simple, and effective therapy is expected to be applied and promoted in the future. In this paper, the detailed pathogenesis, diagnosis, and current clinical treatments for OA are introduced. Then, clinical studies and the therapeutic mechanism of SVF for the treatment of OA are summarized.
Core Tip: Osteoarthritis (OA) is one of the world's leading causes of disability. Clinically, palliative drugs cannot fundamentally cure this disease. The stromal vascular fraction (SVF) from adipose tissues is a heterogeneous cell population. According to studies, it contains a large number of mesenchymal stem cells, which have been used to treat OA with good therapeutic effects. In this review, we present an updated status of the comprehensive and systematic review of pathogenesis, diagnosis, and current clinical treatments for OA, especially focusing on therapeutic applications of adipose-derived SVF.
